MA39055B1 - Nouveaux dérivés d'aminopyrimidine - Google Patents

Nouveaux dérivés d'aminopyrimidine

Info

Publication number
MA39055B1
MA39055B1 MA39055A MA39055A MA39055B1 MA 39055 B1 MA39055 B1 MA 39055B1 MA 39055 A MA39055 A MA 39055A MA 39055 A MA39055 A MA 39055A MA 39055 B1 MA39055 B1 MA 39055B1
Authority
MA
Morocco
Prior art keywords
aminopyrimidine derivatives
diseases
novel
new
btk
Prior art date
Application number
MA39055A
Other languages
English (en)
Other versions
MA39055A1 (fr
Inventor
Daniela Angst
François Gessier
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA39055A1 publication Critical patent/MA39055A1/fr
Publication of MA39055B1 publication Critical patent/MA39055B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Cette invention concerne de nouveaux dérivés d'aminopyrimidine de formule (i) et des sels pharmaceutiquement acceptables de ceux-ci qui s'avèrent interagir avec la tyrosine kinase de bruton (btk). Ainsi, ces nouvelles aminopyrimidines peuvent être efficaces pour traiter les troubles auto-immuns, les maladies inflammatoires, les maladies allergiques, les maladies des voies aériennes telles que l'asthme et la broncho-pneumopathie chronique obstructive (bpco), le rejet de greffe, et les cancers, par exemple d'origine hématopoïétique, ou les tumeurs solides.
MA39055A 2013-11-29 2014-11-28 Nouveaux dérivés d'aminopyrimidine MA39055B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'aminopyrimidine

Publications (2)

Publication Number Publication Date
MA39055A1 MA39055A1 (fr) 2018-02-28
MA39055B1 true MA39055B1 (fr) 2018-10-31

Family

ID=49674216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39055A MA39055B1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'aminopyrimidine

Country Status (42)

Country Link
US (6) US9512084B2 (fr)
EP (5) EP3689865B1 (fr)
JP (2) JP6342495B2 (fr)
KR (2) KR102380539B1 (fr)
CN (2) CN110172056B (fr)
AP (1) AP2016009158A0 (fr)
AR (1) AR098549A1 (fr)
AU (1) AU2014356069B2 (fr)
BR (1) BR112016010397B1 (fr)
CA (1) CA2926908C (fr)
CL (1) CL2016001055A1 (fr)
CR (1) CR20160244A (fr)
CU (1) CU24384B1 (fr)
CY (3) CY1119705T1 (fr)
DK (3) DK3689865T3 (fr)
EA (1) EA031218B1 (fr)
EC (1) ECSP16054826A (fr)
ES (4) ES2947770T3 (fr)
FI (1) FI3689865T3 (fr)
HR (3) HRP20230585T1 (fr)
HU (3) HUE062248T2 (fr)
IL (1) IL244943B (fr)
JO (1) JO3314B1 (fr)
LT (3) LT3074386T (fr)
MA (1) MA39055B1 (fr)
MX (1) MX367911B (fr)
MY (2) MY179059A (fr)
NO (1) NO3074386T3 (fr)
NZ (1) NZ718835A (fr)
PE (1) PE20160869A1 (fr)
PH (1) PH12016500791B1 (fr)
PL (3) PL3299368T3 (fr)
PT (3) PT3299368T (fr)
RS (3) RS60251B1 (fr)
SI (3) SI3689865T1 (fr)
SV (1) SV2016005206A (fr)
TN (1) TN2016000128A1 (fr)
TW (1) TWI652261B (fr)
UA (1) UA117256C2 (fr)
UY (1) UY35858A (fr)
WO (1) WO2015079417A1 (fr)
ZA (1) ZA201602275B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (fr) 2014-08-14 2016-02-18 Novartis Ag Traitement du cancer à l'aide du récepteur d'antigène chimérique gfr alpha-4
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016061142A1 (fr) 2014-10-14 2016-04-21 Novartis Ag Molécules d'anticorps de pd-l1 et leurs utilisations
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3280795B1 (fr) * 2015-04-07 2021-03-24 Novartis AG Combinaison de traitement à l'aide du récepteur antigénique chimérique et de derivés de l'amino pyrimidine
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2017019897A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Polythérapies comprenant des molécules d'anticorps contre tim -3
EP4378957A3 (fr) 2015-07-29 2024-08-07 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3389712B1 (fr) 2015-12-17 2024-04-10 Novartis AG Molécules d'anticorps anti-pd-1 et leurs utilisations
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
CA3016287A1 (fr) 2016-03-04 2017-09-08 Novartis Ag Cellules exprimant de multiples molecules de recepteur d'antigene chimere (car) et leurs utilisations
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
WO2018067992A1 (fr) 2016-10-07 2018-04-12 Novartis Ag Récepteurs antigéniques chimériques pour le traitement du cancer
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
EP3644721A1 (fr) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Modèle murin pour évaluer des toxicités associées à des immunothérapies
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
CA3080904A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Anticorps et recepteurs antigeniques chimeriques specifiques de l'antigene de maturation des lymphocytes b
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
KR20200116081A (ko) 2017-12-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포의 투약 및 조절 방법
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
WO2019118937A1 (fr) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
EP3788369A1 (fr) 2018-05-01 2021-03-10 Novartis Ag Biomarqueurs pour évaluer des cellules car-t pour prédire un résultat clinique
WO2019227003A1 (fr) 2018-05-25 2019-11-28 Novartis Ag Polythérapie comprenant des thérapies par récepteur antigénique chimérique (car)
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
CN120904205A (zh) 2018-08-29 2025-11-07 安塞塔制药公司 制备阿卡拉布替尼的方法
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
EP3880238A1 (fr) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Méthodes de posologie pour cellules t modifiées pour le traitement de cancers à cellules b
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
CA3123303A1 (fr) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Anticorps et recepteurs antigeniques chimeriques specifiques du recepteur orphelin-1 de type recepteur a tyrosine kinase (ror1)
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020234780A1 (fr) 2019-05-23 2020-11-26 Novartis Ag Méthodes de traitement de l'asthme au moyen d'un inhibiteur de la tyrosine kinase de bruton
BR112021023110A2 (pt) * 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
EP4599894A3 (fr) 2019-05-23 2025-11-12 Novartis AG Procédés de traitement de l'urticaire chronique spontanée à l'aide d'un inhibiteur de tyrosine kinase de bruton s
MX2021014157A (es) * 2019-05-23 2022-01-04 Novartis Ag Formas cristalinas de un inhibidor btk.
JP7646671B2 (ja) * 2019-12-23 2025-03-17 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
WO2022033569A1 (fr) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 Formes cristallines de composés benzamide et leur procédé de préparation
CN116157404B (zh) 2020-08-14 2025-10-14 诺华股份有限公司 杂芳基取代的螺哌啶基衍生物及其药物用途
CN116782888A (zh) * 2021-01-26 2023-09-19 诺华股份有限公司 药物组合物
MX2023008671A (es) 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.
WO2022212893A1 (fr) 2021-04-02 2022-10-06 Biogen Ma Inc. Méthodes de traitement combiné de la sclérose en plaques
WO2023031840A1 (fr) 2021-09-03 2023-03-09 Novartis Ag Lou064 pour le traitement de la sclérose en plaques
IL313079A (en) 2021-12-14 2024-07-01 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023250400A1 (fr) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN120051298A (zh) 2022-08-05 2025-05-27 朱诺治疗学股份有限公司 Gprc5d和bcma特异性嵌合抗原受体
KR20250079180A (ko) 2022-09-30 2025-06-04 노파르티스 아게 레미브루티닙의 제조를 위한 합성 방법 및 중간체
WO2024129778A2 (fr) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Récepteurs antigéniques chimériques spécifiques de baff-r et cd19 et procédés et utilisations associés
TW202515850A (zh) * 2023-09-22 2025-04-16 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基類化合物、其製備方法及其在醫藥上的應用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
TW202602859A (zh) 2024-04-02 2026-01-16 瑞士商諾華公司 製備基本上不含亞硝胺雜質的瑞布替尼之方法
WO2026020055A2 (fr) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Procédés d'évaluation d'exosomes dans une composition cellulaire et utilisations associées

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2426508A1 (fr) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulateurs de tyrosine kinase de bruton et intermediaires de tyrosine kinase de bruton et leurs procedes d'identification et d'utilisation dans le traitement et la prevention de l'osteoporose et d'etats pathologiques connexes
SG159378A1 (en) 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
EP1576137A4 (fr) 2002-10-29 2010-06-30 Genentech Inc Compositions et methodes de traitement de maladies liees au systeme immunitaire
WO2004052359A1 (fr) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Procede d'inhibition selective de la janus tyrosine kinase 3 (jak3)
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
EP1473039A1 (fr) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'inhibiteurs et d'oligonucleotitides antisense de BTK pour le traitement de la mastocytose proliferative
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
WO2006099075A2 (fr) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Amides substitues, procede pour les produire et procede pour les utiliser
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
CA2680589A1 (fr) 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Composes modulateurs de la pharmacoresistance dans des cellules tumorales epitheliales
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
CA2728683C (fr) 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Nouvelles phenylpyrazinones en tant qu'inhibiteurs de kinases
CA2730930C (fr) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (fr) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibiteurs de la tyrosien kinase de bruton
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
AR080328A1 (es) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
HUE048834T2 (hu) 2011-05-17 2020-08-28 Univ California Kináz inhibitorok
EA031153B1 (ru) 2011-06-10 2018-11-30 Мерк Патент Гмбх Применение пиримидиновых соединений с btk ингибирующей активностью
BR112013033534A2 (pt) 2011-06-28 2017-02-07 Pharmacyclics Inc métodos e composições para inibição de reabsorção de osso
KR20140058543A (ko) 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
EP3778896A1 (fr) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
CN110801454A (zh) 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
JP5832664B2 (ja) 2011-12-09 2015-12-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013157021A1 (fr) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales de ceux-ci
WO2013157022A1 (fr) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Composés hétéro-bicycliques substitués, compositions et leurs applications médicinales
WO2013173518A1 (fr) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
CA2887435A1 (fr) 2012-10-04 2014-04-10 University Of Utah Research Foundation Analogues de n-(3-(pyrimidin-4-yl)phenyl) substitue utilises en tant qu'inhibiteurs de recepteur tyrosine kinase btk
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
ES2947770T3 (es) 2023-08-18
PE20160869A1 (es) 2016-09-08
KR102380539B1 (ko) 2022-03-29
HRP20171999T1 (hr) 2018-02-09
HUE062248T2 (hu) 2023-10-28
CU24384B1 (es) 2019-03-04
EP3074386A1 (fr) 2016-10-05
FI3689865T3 (fi) 2023-06-12
ZA201602275B (en) 2017-08-30
EP3689865B1 (fr) 2023-03-29
HRP20200775T1 (hr) 2020-07-24
EP3074386B1 (fr) 2017-10-11
TW201609666A (zh) 2016-03-16
KR102421388B1 (ko) 2022-07-18
PT3689865T (pt) 2023-06-16
WO2015079417A1 (fr) 2015-06-04
CY1122924T1 (el) 2021-10-29
MA39055A1 (fr) 2018-02-28
PL3689865T3 (pl) 2023-07-31
CN110172056A (zh) 2019-08-27
EP3689865A1 (fr) 2020-08-05
JO3314B1 (ar) 2019-03-13
JP6667573B2 (ja) 2020-03-18
TN2016000128A1 (en) 2017-10-06
US10457647B2 (en) 2019-10-29
US20230312483A1 (en) 2023-10-05
ES2791525T3 (es) 2020-11-04
SI3689865T1 (sl) 2023-07-31
SI3074386T1 (en) 2018-02-28
CR20160244A (es) 2016-07-29
AU2014356069A1 (en) 2016-05-05
AR098549A1 (es) 2016-06-01
MY191381A (en) 2022-06-22
HUE037588T2 (hu) 2018-09-28
DK3074386T3 (en) 2018-01-22
EP3299368B1 (fr) 2020-02-26
US20200010426A1 (en) 2020-01-09
CY1126056T1 (el) 2023-11-15
HK1223368A1 (en) 2017-07-28
JP6342495B2 (ja) 2018-06-13
CA2926908C (fr) 2021-10-26
HRP20230585T1 (hr) 2023-09-01
IL244943B (en) 2020-04-30
US20220041561A1 (en) 2022-02-10
CU20160078A7 (es) 2016-09-30
PH12016500791A1 (en) 2016-06-13
JP2018141005A (ja) 2018-09-13
CN105683181B (zh) 2019-04-23
US9512084B2 (en) 2016-12-06
MX367911B (es) 2019-09-11
DK3689865T3 (en) 2023-06-19
RS64275B1 (sr) 2023-07-31
IL244943A0 (en) 2016-05-31
KR20160088877A (ko) 2016-07-26
CA2926908A1 (fr) 2015-06-04
ES3040769T3 (en) 2025-11-04
US20180251432A1 (en) 2018-09-06
RS60251B1 (sr) 2020-06-30
UY35858A (es) 2015-06-30
BR112016010397A8 (pt) 2020-04-22
SI3299368T1 (sl) 2020-07-31
US20160235746A1 (en) 2016-08-18
LT3299368T (lt) 2020-05-25
PT3299368T (pt) 2020-05-28
CN105683181A (zh) 2016-06-15
US11673868B2 (en) 2023-06-13
NO3074386T3 (fr) 2018-03-10
LT3074386T (lt) 2017-12-27
EA201691125A1 (ru) 2016-09-30
EP4219478B1 (fr) 2025-06-11
BR112016010397B1 (pt) 2023-04-11
MY179059A (en) 2020-10-26
HUE049794T2 (hu) 2020-10-28
MX2016006908A (es) 2016-08-17
EP3299368A1 (fr) 2018-03-28
AP2016009158A0 (en) 2016-04-30
ES2655527T3 (es) 2018-02-20
PL3074386T3 (pl) 2018-03-30
US11180460B2 (en) 2021-11-23
KR20220044370A (ko) 2022-04-07
SV2016005206A (es) 2016-11-21
RS56657B1 (sr) 2018-03-30
TWI652261B (zh) 2019-03-01
CN110172056B (zh) 2022-04-19
CY1119705T1 (el) 2018-06-27
JP2016538313A (ja) 2016-12-08
LT3689865T (lt) 2023-07-10
UA117256C2 (uk) 2018-07-10
PT3074386T (pt) 2017-11-15
EP4606377A2 (fr) 2025-08-27
PL3299368T3 (pl) 2020-08-10
EA031218B1 (ru) 2018-12-28
ECSP16054826A (es) 2017-10-31
NZ718835A (en) 2021-12-24
PH12016500791B1 (en) 2016-06-13
HK1252317A1 (en) 2019-05-24
EP4219478A1 (fr) 2023-08-02
DK3299368T3 (da) 2020-05-25
CL2016001055A1 (es) 2016-10-28
EP4606377A3 (fr) 2025-11-26
US20150152068A1 (en) 2015-06-04
AU2014356069B2 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
MA39055A1 (fr) Nouveaux dérivés d'aminopyrimidine
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
MA35285B1 (fr) Indazoles
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA41625A (fr) Composés de benzazépine dicarboxamide
BR112015021888A2 (pt) inibidores de dna-ik
EA201491592A1 (ru) Соединения индолов и индазолов, активирующие ampk
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
BR112017011798A2 (pt) 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
BR112015014701A2 (pt) derivados de benzimidazol como inibidores de quinase
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
EP4275756A3 (fr) Dérivés de bipyrazole servant d'inhibiteurs de jak
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA201270561A1 (ru) Антагонисты рецептора cgrp
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
EA201790072A1 (ru) Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы